Business
Exercise of options and total voting rights
Abingdon Health plc has announced the exercise of share options, resulting in the application for 5,208 new ordinary shares to be admitted to trading on AIM on December 30, 2025. Following this issuance, the company's total issued ordinary shares will be 251,077,850, with no shares held in treasury. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency Rules. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n \nThis announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n\n \nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\n \nExercise of options and total voting rights\n \nYork, U.K. 29 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that it has applied for 5,208 new ordinary shares of 0.025 pence each (\"Ordinary Shares\") in the Company to be admitted to trading on AIM on 30 December 2025 following an exercise of share options.\n \nFollowing the issue of the 5,208 new Ordinary Shares the Company will have a total of 251,077,850 Ordinary Shares in issue. The Company does not hold any shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.\n \nEnquiries:\n \n\n\n\n\nAbingdon Health plc\n\n\nwww.abingdonhealth.com/investors/\n\n\n\n\nChris Hand, Executive Chairman\n \n\n\nVia Walbrook PR\n\n\n\n\nTom Hayes, CFO\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nZeus (Sole Broker and Nominated Adviser)\n\n\n Tel: +44 (0)20 3829 5000\n\n\n\n\nAntonio Bossi / Jacob Walker (Corporate Finance)\n\n\n\n\n\n\n\n \n \n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR (Media & Investor Relations)\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n \n\n \nAbout Abingdon Health\n \nAbingdon Health Group is a leading med-tech contract service provider offering its services to an internationa...